5-(cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-6-methoxyisoquinolin-1-amine | 1001061-28-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-(cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-6-methoxyisoquinolin-1-amine
• 英文别名: 5-cyclopentyloxy-N-(3,5-dichloropyridin-4-yl)-6-methoxyisoquinolin-1-amine
• CAS: 1001061-28-4
• 化学式: C₂₀H₁₉Cl₂N₃O₂
• 分子量: 404.296
• InChiKey: PHIWHTOIEFIDDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  56.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-氨基-3,5-二氯吡啶 、 1-Chloro-5-(cyclopentyloxy)-6-methoxyisoquinoline 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 5-(cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-6-methoxyisoquinolin-1-amine
  参考文献：
  名称：

  Water-soluble PDE4 inhibitors for the treatment of dry eye

  摘要：

  PDE4 inhibitors have the potential to alleviate the symptoms and underlying inflammation associated with dry eye. Disclosed herein is the development of a novel series of water-soluble PDE4 inhibitors. Our studies led to the discovery of coumarin 18, which is effective in a rabbit model of dry eye and a tear secretion test in rats. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.023

文献信息

• BICYCLIC HETEROARYL INHIBITORS OF PDE4
  申请人：Govek Steven P.

  公开号：US20090291950A1

  公开（公告）日：2009-11-26

  The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PD E4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.

  本发明涉及化合物和方法，可用作磷酸二酯酶4（PDE4）的抑制剂，用于治疗或预防炎症性疾病和其他涉及细胞因子和促炎介质水平升高的疾病。
• [EN] BICYCLIC HETEROARYL INHIBITORS OF PDE4<br/>[FR] INHIBITEURS DE PDE4 À BASE DE COMPOSÉS D'HÉTÉROARYLE BICYCLIQUE
  申请人：GOVEK STEVEN P

  公开号：WO2008006052A2

  公开（公告）日：2008-01-10

  [EN] The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PD E4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
  [FR] La présente invention concerne des composés pouvant être utiles comme inhibiteurs de la phosphodiestérase 4 (PDE4), ainsi que des procédés associés. Ces composés et ces procédés sont destinés au traitement ou à la prévention de maladies inflammatoires et d'autres maladies associées à des taux élevés de cytokines et de médiateurs pro-inflammatoires.
• Water-soluble PDE4 inhibitors for the treatment of dry eye
  作者：Steven P. Govek、Guy Oshiro、John V. Anzola、Clay Beauregard、Jasmine Chen、Avery R. Coyle、Daniel A. Gamache、Mark R. Hellberg、Jennifer N. Hsien、Julia M. Lerch、John C. Liao、James W. Malecha、Lena M. Staszewski、David J. Thomas、John M. Yanni、Stewart A. Noble、Andrew K. Shiau

  DOI：10.1016/j.bmcl.2010.03.023

  日期：2010.5

  PDE4 inhibitors have the potential to alleviate the symptoms and underlying inflammation associated with dry eye. Disclosed herein is the development of a novel series of water-soluble PDE4 inhibitors. Our studies led to the discovery of coumarin 18, which is effective in a rabbit model of dry eye and a tear secretion test in rats. (C) 2010 Elsevier Ltd. All rights reserved.